Gain Therapeutics plans Phase 2 trial of rexaceract in Parkinson's disease for Q1 2027 start

Bitget2026/10/01 13:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Gain Therapeutics disclosed new long-term Phase 1b extension results for rexaceract in Parkinson’s disease, slated for poster presentation Oct. 4-8, 2026.
Patient motor assessments remained broadly stable over a year of dosing, supporting a potential disease-modifying profile.
Safety profile stayed consistent over 12 months, with no new signals reported in the extension period.
Management plans to file a Phase 2 protocol with the FDA in coming weeks, targeting trial initiation in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-112624), on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Gain Therapeutics plans Phase 2 trial of rexaceract in Parkinson's disease for Q1 2027 start

You may also like

Crypto prices